301 related articles for article (PubMed ID: 29158605)
1. Deep sequencing of HIV-1 reverse transcripts reveals the multifaceted antiviral functions of APOBEC3G.
Pollpeter D; Parsons M; Sobala AE; Coxhead S; Lang RD; Bruns AM; Papaioannou S; McDonnell JM; Apolonia L; Chowdhury JA; Horvath CM; Malim MH
Nat Microbiol; 2018 Feb; 3(2):220-233. PubMed ID: 29158605
[TBL] [Abstract][Full Text] [Related]
2. The Disassociation of A3G-Related HIV-1 cDNA G-to-A Hypermutation to Viral Infectivity.
Martin J; Chen X; Jia X; Shao Q; Liu B
Viruses; 2024 May; 16(5):. PubMed ID: 38793610
[TBL] [Abstract][Full Text] [Related]
3. APOBEC3G inhibits elongation of HIV-1 reverse transcripts.
Bishop KN; Verma M; Kim EY; Wolinsky SM; Malim MH
PLoS Pathog; 2008 Dec; 4(12):e1000231. PubMed ID: 19057663
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
5. The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication.
Wang X; Ao Z; Chen L; Kobinger G; Peng J; Yao X
J Virol; 2012 Apr; 86(7):3777-86. PubMed ID: 22301159
[TBL] [Abstract][Full Text] [Related]
6. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G.
Iwatani Y; Chan DS; Wang F; Stewart-Maynard K; Sugiura W; Gronenborn AM; Rouzina I; Williams MC; Musier-Forsyth K; Levin JG
Nucleic Acids Res; 2007; 35(21):7096-108. PubMed ID: 17942420
[TBL] [Abstract][Full Text] [Related]
7. APOBEC3G inhibits HIV-1 RNA elongation by inactivating the viral trans-activation response element.
Nowarski R; Prabhu P; Kenig E; Smith Y; Britan-Rosich E; Kotler M
J Mol Biol; 2014 Jul; 426(15):2840-53. PubMed ID: 24859335
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
[TBL] [Abstract][Full Text] [Related]
9. Repair of APOBEC3G-Mutated Retroviral DNA
Salas-Briceno K; Ross SR
J Virol; 2021 Oct; 95(22):e0124421. PubMed ID: 34468176
[TBL] [Abstract][Full Text] [Related]
10. DNA mutagenic activity and capacity for HIV-1 restriction of the cytidine deaminase APOBEC3G depend on whether DNA or RNA binds to tyrosine 315.
Polevoda B; Joseph R; Friedman AE; Bennett RP; Greiner R; De Zoysa T; Stewart RA; Smith HC
J Biol Chem; 2017 May; 292(21):8642-8656. PubMed ID: 28381554
[TBL] [Abstract][Full Text] [Related]
11. Dimerization regulates both deaminase-dependent and deaminase-independent HIV-1 restriction by APOBEC3G.
Morse M; Huo R; Feng Y; Rouzina I; Chelico L; Williams MC
Nat Commun; 2017 Sep; 8(1):597. PubMed ID: 28928403
[TBL] [Abstract][Full Text] [Related]
12. APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells.
Anderson JL; Hope TJ
Virology; 2008 May; 375(1):1-12. PubMed ID: 18308358
[TBL] [Abstract][Full Text] [Related]
13. Multi-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapy.
Hosseini I; Mac Gabhann F
PLoS Comput Biol; 2012 Feb; 8(2):e1002371. PubMed ID: 22346743
[TBL] [Abstract][Full Text] [Related]
14. Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection.
Ao Z; Yu Z; Wang L; Zheng Y; Yao X
PLoS One; 2008 Apr; 3(4):e1995. PubMed ID: 18414671
[TBL] [Abstract][Full Text] [Related]
15. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
Bishop KN; Holmes RK; Malim MH
J Virol; 2006 Sep; 80(17):8450-8. PubMed ID: 16912295
[TBL] [Abstract][Full Text] [Related]
16. Retroviral restriction factor APOBEC3G delays the initiation of DNA synthesis by HIV-1 reverse transcriptase.
Adolph MB; Webb J; Chelico L
PLoS One; 2013; 8(5):e64196. PubMed ID: 23717565
[TBL] [Abstract][Full Text] [Related]
17. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
[TBL] [Abstract][Full Text] [Related]
18. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
Holmes RK; Koning FA; Bishop KN; Malim MH
J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Escape from Small-Molecule Antagonism of Vif.
Sharkey M; Sharova N; Mohammed I; Huff SE; Kummetha IR; Singh G; Rana TM; Stevenson M
mBio; 2019 Feb; 10(1):. PubMed ID: 30808702
[TBL] [Abstract][Full Text] [Related]
20. The HIV-1 central polypurine tract functions as a second line of defense against APOBEC3G/F.
Hu C; Saenz DT; Fadel HJ; Walker W; Peretz M; Poeschla EM
J Virol; 2010 Nov; 84(22):11981-93. PubMed ID: 20844042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
